Last reviewed · How we verify
ISV-403
ISV-403 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation.
ISV-403 is a small molecule that inhibits the Wnt/β-catenin signaling pathway to reduce corneal neovascularization and inflammation. Used for Corneal neovascularization, Corneal scarring and fibrosis.
At a glance
| Generic name | ISV-403 |
|---|---|
| Also known as | besifloxacin, Besivance, BOL-303224 |
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Wnt/β-catenin pathway inhibitor |
| Target | Wnt/β-catenin signaling pathway |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
ISV-403 targets the Wnt signaling cascade, which plays a key role in pathological corneal neovascularization and fibrosis. By inhibiting this pathway, the drug aims to suppress abnormal blood vessel growth and reduce inflammatory responses in the cornea, thereby improving visual outcomes in corneal diseases.
Approved indications
- Corneal neovascularization
- Corneal scarring and fibrosis
Common side effects
Key clinical trials
- A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis (PHASE3)
- A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. (PHASE3)
- Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis (PHASE2)
- Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days (PHASE1)
- Systemic Pharmacokinetics of BOL-303224-A (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |